Summary:
- Vigil Neuroscience, a clinical-stage biopharmaceutical company, has entered into a definitive merger agreement to be acquired by Athira Pharma, Inc.
- The merger aims to combine the companies' expertise in developing novel therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's.
- The combined entity will have a robust pipeline of drug candidates targeting various stages of these debilitating neurological disorders, with the goal of improving the lives of patients and their families.